The FDA approved Neurizon’s NUZ-001 for a major ALS trial testing new treatments.

Aspire Biopharma gets Nasdaq extension to fix compliance issues and restructure, moving markets Dec. 15, 2025.

Acupuncture, real or sham, eased cognitive issues in breast cancer survivors, with real acupuncture showing lasting benefits.

Two Madrigal execs sold $24M in stock amid company's quarterly loss and delayed drug trial.

Over 300 global heart specialists trained in advanced complication management at a Chennai-based interventional course.

Terns Pharmaceuticals shares surged 53% on Dec. 14, 2025, after early trial results showed promising leukemia treatment results.

OMRON expands global ECG business with AI-driven remote heart monitoring in India and Japan.

Cancer patients with severe heart valve disease face higher death risk, but treatment cuts it by 72%, urging routine heart checks.

Crinetics begins Phase 3 trial for atumelnant, an oral drug targeting classic congenital adrenal hyperplasia by blocking ACTH receptors.

A new robotic biopsy system boosts lung cancer detection accuracy to 92% and enables same-day results, reducing anxiety and surgeries.